- Home
- OPRT vs VNDA Comparison
OPRT vs VNDA Comparison
Compare OPRT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- VNDA
- Stock Information
- Founded
- OPRT 2005
- VNDA 2002
- Country
- OPRT United States
- VNDA United States
- Employees
- OPRT N/A
- VNDA N/A
- Industry
- OPRT Finance: Consumer Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- VNDA Health Care
- Exchange
- OPRT Nasdaq
- VNDA Nasdaq
- Market Cap
- OPRT 290.9M
- VNDA 249.4M
- IPO Year
- OPRT 2019
- VNDA 2006
- Fundamental
- Price
- OPRT $6.56
- VNDA $4.52
- Analyst Decision
- OPRT Hold
- VNDA Strong Buy
- Analyst Count
- OPRT 2
- VNDA 2
- Target Price
- OPRT $8.00
- VNDA $16.50
- AVG Volume (30 Days)
- OPRT 604.4K
- VNDA 421.3K
- Earning Date
- OPRT 11-11-2025
- VNDA 11-05-2025
- Dividend Yield
- OPRT N/A
- VNDA N/A
- EPS Growth
- OPRT N/A
- VNDA N/A
- EPS
- OPRT N/A
- VNDA N/A
- Revenue
- OPRT $724,757,000.00
- VNDA $203,467,000.00
- Revenue This Year
- OPRT $27.48
- VNDA $15.45
- Revenue Next Year
- OPRT $5.29
- VNDA $37.82
- P/E Ratio
- OPRT N/A
- VNDA N/A
- Revenue Growth
- OPRT N/A
- VNDA 11.78
- 52 Week Low
- OPRT $2.37
- VNDA $3.81
- 52 Week High
- OPRT $9.25
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- OPRT 54.01
- VNDA 48.11
- Support Level
- OPRT $6.14
- VNDA $4.54
- Resistance Level
- OPRT $6.95
- VNDA $4.64
- Average True Range (ATR)
- OPRT 0.32
- VNDA 0.15
- MACD
- OPRT 0.01
- VNDA -0.01
- Stochastic Oscillator
- OPRT 62.75
- VNDA 14.44
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.